Utah is currently home to 1209 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116
Recruiting
An open label phase 3 study
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Sunpharma site no 96, Salt Lake City, Utah
Conditions: Psoriatic Arthritis
Register for Updates
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
NCT05446272
Recruiting
DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0/7-28 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.
Gender:
ALL
Ages:
Between 0 days and 9 weeks
Trial Updated:
06/13/2025
Locations: Intermountain Medical Center, Murray, Utah
Conditions: Extubation Failure, Bronchopulmonary Dysplasia, Death
Register for Updates
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236
Recruiting
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City, Utah
Conditions: Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma
Register for Updates
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022
Recruiting
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Register for Updates
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626
Recruiting
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-00... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Register for Updates
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
NCT05329103
Recruiting
This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: Advanced Solid Tumor
Register for Updates
Study of LYL314 in Aggressive Large B-Cell Lymphoma
NCT05826535
Recruiting
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Register for Updates
Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas
NCT03542409
Recruiting
This study evaluates the use of specialized magnetic resonance imaging (MRI) techniques including magnetic resonance (MR) perfusion and 2-hydroxyglutarate (2HG) spectroscopy in the surgical treatment of gliomas. Cohort 1 participants will undergo an MR perfusion scan or 2-HG spectroscopy prior to surgery and intra-operatively. Cohort 2 participants will only undergo standard of care imaging and tumor acquisition. Participant participation will end at the completion of surgery and will be trans... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Brain Tumor Adult
Register for Updates
A Study of Mosliciguat in PH-ILD
NCT06635850
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: University of Utah Health, Salt Lake City, Utah
Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Register for Updates
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients
NCT06875700
Recruiting
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarcoma and other cancer risks, and attitudes towards germline testing among leiomyosarcoma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
Conditions: Leiomyosarcoma
Register for Updates
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
NCT05346484
Recruiting
This is an open-label, dose-escalation, multi-center phase I study evaluating the safety of CF33-hNIS (hNIS - human sodium iodide symporter) administered via two routes of administration, intratumoral (IT) or intravenous (IV), either as a monotherapy or in combination with pembrolizumab or mFOLFOX in patients with metastatic or advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
Register for Updates
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
NCT03550391
Recruiting
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hipp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Conditions: Brain Metastases
Register for Updates